BIOMAT Database Logo BIOMAT Database Logo

Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis. 1998

D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, Paris, France. diane.descamps@bch.ap-hop-paris.fr

We compared the line probe assay (LiPA) to sequence analysis for the detection of mutations conferring resistance to nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). Plasma samples from 40 patients who had received zidovudine, dideoxyinosine, and dideoxycytosine, alone or in combination, and who were enrolled in the ALTIS 2 clinical trial (lamivudine [3TC] plus stavudine) were tested at enrollment and at week 24. RT PCR products from plasma were used for LiPA, and DNA was used for sequence analysis. LiPA gave uninterpretable results for 8.5% of the analyzed codons corresponding to 63 samples, mainly for codons 41, 69, and 70. Several minor discrepancies between the two methods occurred, mainly due to the ability of LiPA to detect mixed populations while sequence analyses detect a single homogeneous population. LiPA is suitable for detecting mixed populations and easy to implement in clinical laboratories and might be useful for epidemiological surveys of primary HIV-1 resistance.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015336 Molecular Probe Techniques The use of devices which use detector molecules to detect, investigate, or analyze other molecules, macromolecules, molecular aggregates, or organisms. Molecular Probe Technic,Molecular Probe Technics,Molecular Probe Technique,Technic, Molecular Probe,Technics, Molecular Probe,Technique, Molecular Probe,Techniques, Molecular Probe,Probe Technic, Molecular,Probe Technics, Molecular,Probe Technique, Molecular,Probe Techniques, Molecular
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017422 Sequence Analysis, DNA A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis. DNA Sequence Analysis,Sequence Determination, DNA,Analysis, DNA Sequence,DNA Sequence Determination,DNA Sequence Determinations,DNA Sequencing,Determination, DNA Sequence,Determinations, DNA Sequence,Sequence Determinations, DNA,Analyses, DNA Sequence,DNA Sequence Analyses,Sequence Analyses, DNA,Sequencing, DNA
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
Frequency of mutations conferring resistance to nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected patients in Korea.
April 2002, Journal of clinical microbiology,
D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.
March 1995, The Journal of infectious diseases,
D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
January 2004, Current topics in medicinal chemistry,
D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene.
February 1997, Antimicrobial agents and chemotherapy,
D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
August 2006, Antimicrobial agents and chemotherapy,
D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors.
July 2006, Journal of virology,
D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
January 2005, Journal of virology,
D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.
October 2001, Journal of virology,
D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.
July 2002, Antimicrobial agents and chemotherapy,
D Descamps, and V Calvez, and G Collin, and A Cécille, and C Apetrei, and F Damond, and C Katlama, and S Matheron, and J M Huraux, and F Brun-Vézinet
Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.
May 1997, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!